Explanation
tisassociated withreduced cardiovascularrisk
IntheEMPA-REGOUuTCOMEtriau.theeffectsof empaqtiflozin wereexamined on cardiovascular morbidity and
mortalityinpatientswthtvpe2diabetes at hiahriskforcardiovascular events.Patients wthtvpe2diabetes
athiahriskforcardiovasculareventswhoreceivedemoaatiflozin.ascompared with placebo.had alowerrate
oftheprimarycompositecardiovascular outcomeandof deathfrom any cause when thestudy drug was
addedto standardcare.
@1MINENDOCRINE
